|

Stem Cell Applications in Biliary Atresia Patients

RECRUITINGN/ASponsored by Necmi Kadıoğlu Hospital
Actively Recruiting
PhaseN/A
SponsorNecmi Kadıoğlu Hospital
Started2024-06-01
Est. completion2026-05-30
Eligibility
Age2 Months – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06564740

Summary

Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success in treating children with biliary atresia (BA). This study aims to evaluate the efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy in BA through a multicentric randomized controlled trial.

Eligibility

Age: 2 Months – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Infants were diagnosed with liver cirrhosis due to biliary atresia following Kasai's operation.
* The patients two months old or older and exhibited signs of cirrhosis after the procedure, including hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices (confirmed by endoscopy), and cirrhosis (confirmed by liver biopsy).

Exclusion Criteria:

* Epilepsy
* Neurological disorders
* Coagulation disorders
* Diabetes
* Syndromic type biliary atresia
* Allergies to anesthetic agents
* Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys, active infections, and severe psychiatric disorders.

Conditions4

Biliary AtresiaFibrosis, LiverLiver DiseaseStem Cell

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.